Locally Advanced Prostate Cancer Clinical Trial
Official title:
A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
While radiation therapy with androgen ablation (hormone reduction) is the standard method of
treating locally advanced prostate cancer. New treatments are being combined with radiation
therapy in an effort to further improve the cure rates.
This study proposes to combine an experimental drug, TNFerade™ Biologic, (also called
AdGVEGR.TNF.11D or "TNFerade") at different dose (amounts) levels in combination with
radiation.
TNFerade™ Biologic is a form of gene transfer therapy that when injected into the tumor has
shown to increase the effect of radiation therapy.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05590793 -
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
|
Phase 3 | |
| Active, not recruiting |
NCT03350529 -
MRI Guided Transurethral HIFU for Various Prostate Diseases
|
N/A | |
| Recruiting |
NCT05406999 -
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00319787 -
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06130995 -
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT06387056 -
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
|
Phase 2 |